-
Novo Nordisk: Simeglutide 2.4mg shows significant improvement in liver fibrosis symptoms and will submit regulatory approval to the United States and the European Union in the first half of 2025
Southern Finance and Economics, November 2nd - Novo Nordisk announced on its official website on Friday (November 1st) the results of the first phase of an ongoing Phase III trial, in which 2.4 milli ...